Audited Financial Results of the Company for the quarter and year ended March 31, 2026 along with Auditors Report
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novyra Pharmachem Limited reported audited financial results for FY2026 with total revenue of Rs. 16.75 Lakhs (up from Rs. 4.80 Lakhs in FY25). However, the company reported a massive loss before tax of Rs. 537.38 Lakhs compared to a loss of Rs. 6.36 Lakhs in the previous year - an 84x increase in losses. The Tea Estate segment, which contributes the majority of revenue (Rs. 8.94 Lakh), incurred a segment loss of Rs. 449.39 Lakh. Operating cash flow was significantly negative at Rs. 372.31 Lakhs. Total assets declined sharply from Rs. 614.42 Lakhs to Rs. 145.88 Lakhs. The company has three reportable segments: Pharma, Real Estate, and Tea Estate. Statutory auditors D G MS & Co. LLP issued an unmodified (clean) opinion on the results.
The stock may face significant selling pressure due to the enormous increase in losses, negative operating cash flows, and substantial asset shrinkage. The Tea Estate segment appears to be destroying value despite generating most of the revenue, raising concerns about the company's strategic direction and viability.